ASH 2022 Conference Coverage - A Focus on GVHD for Pharmacists
Itacitinib Plus Corticosteroids for Chronic GVHD
At the 64th ASH Annual Meeting and Exposition, researchers presented early findings from the dose-finding portion of GRAVITAS-309, a study on itacitinib combined with...
PTCy, Abatacept, and Tacrolimus for GVHD Prophylaxis
Haploidentical blood and marrow transplantation (BMT) has significantly increased the number of eligible hematopoietic stem cell donors; however, the outcomes of these transplants are...
Baricitinib Plus Standard GVHD Prophylaxis: Phase 1 Results
Researchers, led by Mark A. Schroeder, MD, conducted a single-arm, open-label phase 1 trial to evaluate the safety of baricitinib, a balanced Janus kinase...
The Lasting Impact of Surviving Severe aGVHD
Patients who recover from grade 3-4 acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation (HCT) demonstrated greater risk for late comorbidities, higher rates...
Impact of Ruxolitinib Initiation Timing
Studies suggest that between 35% and 60% of patients with acute graft-versus-host disease (aGVHD) become resistant to corticosteroids. Prolonged corticosteroid therapy also involves increased...
Pilot Data on Fecal Microbiotherapy for Acute GI GVHD
In a presentation at the 64th ASH Annual Meeting and Exposition, researchers presented findings from a pilot study on the pooled allogeneic fecal microbiotherapy...
PRMT5 Identified as Potential GVHD Treatment Target
Previously, Katiri Snyder and colleagues determined that the enzyme protein arginine methyltransferase 5 (PRMT5) was upregulated in acute graft-versus-host disease (aGVHD) and that PRMT5...
Ruxolitinib With Corticosteroids in Pediatric GVHD
In a presentation at the 64th ASH Annual Meeting and Exposition, Franco Locatelli, MD, presented the first evidence reported in the phase 1/2 REACH4...
Belumosudil Significantly Affects IST Serum Concentrations
Recently, the novel Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, belumosudil, was approved for the treatment of chronic graft-versus-host disease (GVHD) in patients...
Adding Itacitinib to Conventional GVHD Prophylaxis
In a recent study, researchers from the Hope National Medical Center in Duarte, California, evaluated the safety and efficacy of adding itacitinib to standard...
